1 Result: CureVac
CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
May 19th, 2023
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login